Raymond James analyst Jayson Bedford maintained a Buy rating on Abbott Labs on Tuesday, setting a price target of $116, which is approximately 9.65% above the present share price of $105.79.
Bedford expects Abbott Labs to post earnings per share (EPS) of $1.00 for the second quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in Abbott Labs, with an average price target of $126.83.
The analysts price targets range from a high of $145 to a low of $116.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $10.46 billion and a net profit of $2.11 billion. The company's market cap is $187.97 billion.
According to TipRanks.com, Raymond James analyst Jayson Bedford is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.8% and a 70.84% success rate.
Abbott Laboratories (NYSE:ABT) offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.